Structured Summary
Abstract
A recombinant human fusion protein of LFA-3 antigen and immunoglobulin IGG1 that binds to CD2 ANTIGENS on memory T-LYMPHOCYTES, preventing their activation and proliferation. It is used in the management of moderate to severe chronic plaque PSORIASIS.
MeSH Record
Classification
Broader headings
Related Concepts
Knowledge Graph
Drag nodes to rearrange; hover to trace links; click a node to open its page.
Drug Class
Pharmacological Action
MeSH Record
Synonyms
4 entry terms
- LFA-3 IgG(1) Fusion Protein
- LFA-3 IgG1 Fusion Protein
- LFA 3 IgG1 Fusion Protein
- Amevive
MeSH Record
Aspects Covered
30 allowable subheadings
Indexed with the subheadings administration & dosage, adverse effects, agonists, analysis, antagonists & inhibitors, biosynthesis, blood, cerebrospinal fluid, chemical synthesis, chemistry, classification, deficiency, drug effects, economics, genetics, history, immunology, isolation & purification, metabolism, pharmacokinetics, pharmacology, physiology, poisoning, radiation effects, standards, supply & distribution, therapeutic use, toxicity, ultrastructure, urine.
MeSH Record
History Note
2019 (2000)
MeSH Hierarchy
Tree Numbers
AMA Style
References
- National Library of Medicine. Alefacept. Medical Subject Headings (MeSH). 2026. Unique ID D000077944. http://id.nlm.nih.gov/mesh/2026/D000077944
- Alefacept. In: Wikipedia. https://en.wikipedia.org/wiki/Alefacept
- Alefacept. In: Wikidata. https://www.wikidata.org/wiki/Q3609421